4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics' update from INGLAXA Phase I/II clinical trials and development plans for 4D-310 genetic medicine for Fabry disease cardiomyopathy webcast. As a reminder, today's call is being recorded.
With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.
Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics 4D-310 program update webcast. A press release describing the results and development plans related to 4D-310 is accessible in the Investors section of the 4D Molecular Therapeutics website, and a recording of this webcast will be accessible on our website after completion of this call.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. PJ Utz, Professor of Medicine, Immunology and Rheumatology at Stanford University. As a reminder, on this call, we will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |